DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.
Location: United States, Massachusetts, Medfield
Employees: 11-50
Total raised: $40M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 01.12.2020 | 5AM Ventur... | 5amventure... |
| - | Atlas Vent... | atlasventu... |
| 16.06.2022 | GIMV | gimv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.12.2020 | Series A | $40M | - |
Mentions in press and media 9
| Date | Title | Description |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases Mon, Jan 12, 2026 13:00 CET Report this content EQT Life Sciences invests in U.S.-based Kinaset Thera... |
| 12.01.2026 | Top Startup and Tech Funding News – January 12, 2025 | It’s Monday, January 12, 2026, and we’re back with today’s top startup and tech funding news. Today’s funding landscape reflects the escalating demand for AI infrastructure, autonomous security, and next-generation therapeutics. From multi-... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding. The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 01.12.2020 | Kinaset Therapeutics launches with $40M | Kinaset Therapeutics, a developer of treatments for respiratory disorders, has raised $40 million from 5AM Ventures, Atlas Venture and Gimv. The biopharma company plans to begin Phase I and I-B clinical trials of a drug designed to treat se... |
| 30.11.2020 | Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a N... | - |
| 30.11.2020 | Kinaset Therapeutics Launches with $40M Series A | MEDFIELD, MA, Kinaset Therapeutics has raised a $40 million Series A financing. >> Click here for more funding data on Kinaset Therapeutics >> To export Kinaset Therapeutics funding data to PDF and Excel, click here Kinas... |
| 30.11.2020 | Kinaset Therapeutics Launches with a $40M Series A Financing | MEDFIELD, Mass.--(BUSINESS WIRE)--Kinaset Therapeutics, Inc., a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Comp... |
| - | Kinaset Therapeutics | “DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.” |